Quinaglute Dura-Tabs en es it fr

Quinaglute Dura-Tabs Brand names, Quinaglute Dura-Tabs Analogs

Quinaglute Dura-Tabs Brand Names Mixture

  • No information avaliable

Quinaglute Dura-Tabs Chemical_Formula

C20H24N2O2

Quinaglute Dura-Tabs RX_link

http://www.rxlist.com/cgi/generic/quinidine.htm

Quinaglute Dura-Tabs fda sheet

Quinaglute_Dura-Tabs FDA

Quinaglute Dura-Tabs msds (material safety sheet)

Quinaglute Dura-Tabs Synthesis Reference

No information avaliable

Quinaglute Dura-Tabs Molecular Weight

324.417 g/mol

Quinaglute Dura-Tabs Melting Point

174 oC

Quinaglute Dura-Tabs H2O Solubility

140 mg/L

Quinaglute Dura-Tabs State

Solid

Quinaglute Dura-Tabs LogP

2.534

Quinaglute Dura-Tabs Dosage Forms

Solution

Quinaglute Dura-Tabs Indication

For the treatment of ventricular pre-excitation and cardiac dysrhythmias

Quinaglute Dura-Tabs Pharmacology

Quinidine, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation.

Quinaglute Dura-Tabs Absorption

No information avaliable

Quinaglute Dura-Tabs side effects and Toxicity

No information avaliable

Quinaglute Dura-Tabs Patient Information

Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

  • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
  • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
  • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
  • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

Quinaglute Dura-Tabs Organisms Affected

Humans and other mammals